2023 Annual Meeting | S17 - Innovations in Neuro-oncology

Date Monday 04/24/23

Time 01:00 PM - 03:00 PM EST Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Scientific Platform Session

Moderator(s) Ashley P. Ghiaseddin, MD, FAAN, Alissa A. Thomas, MD, FAAN

Topic(s) Neuro-oncology

Learning Objectives A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes for question and answer with the author.

CME Available 2.00 CME credits

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic

Event Timeline
01:00 PM - 01:12 PM EST	Speaker	2023 Neuro-oncology Investigator Award: This award recognizes junior investigators who have advanced the field of neuro-oncology. Karisa C. Schreck, MD, PhD
01:12 PM - 01:24 PM EST	Speaker	2023 Neuro-oncology Scientific Award: This award recognizes an individual from any discipline and of any academic rank for a singular scientific achievement that has advanced the field of neuro-oncology. Ingo K. Mellinghoff, MD, FACP
01:24 PM - 01:36 PM EST	Abstract	003 - Identification of the cuproptosis-related gene signature associated with the tumor environment and prognosis of patients with glioblastoma multiforme (GBM) Obada Ababneh
01:36 PM - 01:48 PM EST	Abstract	004 - Pemigatinib For Previously Treated Central Nervous System Tumors With Activating FGFR Mutations or Translocations: Results From FIGHT-207 Iben Spanggaard, MD, PhD
01:48 PM - 02:00 PM EST	Abstract	005 - Safety of Direct Oral Anticoagulants as Compared to Low Molecular Weight Heparin in Treating Venous Thromboembolism in Patients with Primary Brain Tumors and Brain Metastases – A Review of Literature and Meta-analysis Surabhi Ranjan, MD
02:00 PM - 02:12 PM EST	Abstract	006 - Structured Early Advanced Care Planning Outcomes for Patients with High Grade Glioma Meredith Pescatello
02:12 PM - 02:24 PM EST	Abstract	007 - The impact of hippocampal radiation dose on cognitive outcomes in older vs younger adults with brain tumors Sara Hardy, MD
02:24 PM - 02:36 PM EST	Abstract	008 - Soluble ST2 is associated with neurotoxicity following chimeric antigen receptor T-cell therapy Elle Fietsam
02:36 PM - 02:48 PM EST	Abstract	009 - Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival following Immunotherapy in Murine GBM. Michal Nisnboym Ziv, MD
02:48 PM - 03:00 PM EST	Abstract	010 - Comparison of a STIR- and T1-based radiomics model to differentiate between plexiform neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis type 1 (NF1) Scott R. Plotkin, MD, PhD, FAAN

Faculty Disclosures
Justin T. Jordan, MD, MPH, FAAN	Dr. Jordan has received personal compensation for serving as an employee of City of Beverly. An immediate family member of Dr. Jordan has received personal compensation for serving as an employee of Dietitians on Demand. An immediate family member of Dr. Jordan has received personal compensation for serving as an employee of Genesis HR Solutions. Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Navio Theragnostics. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Recursion Pharmaceuticals, Inc. Dr. Jordan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Shepherd Therapeutics. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akeila Bio. Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Springworks Therapeutics. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck Pharmaceuticals. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Continental Casualty Company. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for HennLesperance. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Rhoades McKee. Dr. Jordan has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Wheeler Trigg O'Donnell. Dr. Jordan has stock in Navio Theragnostics. Dr. Jordan has stock in The Doctor Lounge. An immediate family member of Dr. Jordan has stock in OldGate. Dr. Jordan has stock in Akeila Bio. Dr. Jordan has stock in Shepherd Therapeutics. Dr. Jordan has stock in Khora TX. The institution of Dr. Jordan has received research support from NIH. The institution of Dr. Jordan has received research support from Department of Defense. The institution of Dr. Jordan has received research support from PCORI. Dr. Jordan has received publishing royalties from a publication relating to health care. Dr. Jordan has a non-compensated relationship as a board member with United Council for Neurologic Subspecialties that is relevant to AAN interests or activities.
Michelle Janelsins	No disclosure on file
Jan Drappatz, MD	Dr. Drappatz has stock in Pfizer. Dr. Drappatz has stock in Vertex. Dr. Drappatz has stock in GSK. The institution of Dr. Drappatz has received research support from Servier. Dr. Drappatz has received publishing royalties from a publication relating to health care.
Nimish A. Mohile, MD, FAAN	The institution of Dr. Mohile has received research support from Novocure.
W. T. Kimberly, MD, PhD	Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrocyte Pharmaceuticals. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acasti Pharma. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hyperfine Inc.. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics. Dr. Kimberly has stock in Woolsey Pharmaceuticals. Dr. Kimberly has stock in Acasti Pharma. The institution of Dr. Kimberly has received research support from Biogen. The institution of Dr. Kimberly has received research support from NControl Therapeutics. The institution of Dr. Kimberly has received research support from NIH. The institution of Dr. Kimberly has received research support from American Heart Association. The institution of Dr. Kimberly has received research support from Hyperfine, Inc.. Dr. Kimberly has received intellectual property interests from a discovery or technology relating to health care.
Sara Hardy, MD	Dr. Hardy has received research support from the American Cancer Society.
	No disclosure on file
Surabhi Ranjan, MD	Dr. Ranjan has nothing to disclose.
Frank Lieberman, MD	The institution of Dr. Lieberman has received research support from Novocure. The institution of Dr. Lieberman has received research support from Black Diamond. The institution of Dr. Lieberman has received research support from Chimerix. The institution of Dr. Lieberman has received research support from Abbvie.
Michael Milano	Michael Milano has received publishing royalties from a publication relating to health care.
Yoshie Umemura, MD	Dr. Umemura has received personal compensation for serving as an employee of Dignity Health. Dr. Umemura has received personal compensation for serving as an employee of University of Michigan. Dr. Umemura has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Servier. The institution of Dr. Umemura has received research support from Gateway for Cancer Research.
Dhivyaa Rajasundaram	No disclosure on file
Jaishri Blakeley, MD, FAAN	Dr. Blakeley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Springworks Therapeutics.
Denise Leung, MD, MS, FAAN	Dr. Leung has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Servier. Dr. Leung has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Curio.
Deborah T. Blumenthal, MD	Dr. Blumenthal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier Affaires Medicales. Dr. Blumenthal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novocure Israel Ltd. Dr. Blumenthal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda Oncology. The institution of Dr. Blumenthal has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Merck Sharp and Dohme.
Koren Holley	Ms. Holley has nothing to disclose.
Olivia Michaels	Ms. Michaels has nothing to disclose.
Lauryn Hemminger	Dr. Hemminger has nothing to disclose.
Santosh Kesari, MD, PhD, FAAN	Dr. Kesari has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for xcures. Dr. Kesari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Duke.
Larry Junck, MD	Dr. Junck has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Orbus Therapeutics. Dr. Junck has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Servier Pharmaceuticals, LLC. Dr. Junck has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Bowman & Brooke.
Iben Spanggaard, MD, PhD	Dr. Spanggaard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca. The institution of Dr. Spanggaard has received research support from Roche. The institution of Dr. Spanggaard has received research support from Genentech. The institution of Dr. Spanggaard has received research support from Astra-Zeneca. The institution of Dr. Spanggaard has received research support from Incyte. The institution of Dr. Spanggaard has received research support from Pfizer. The institution of Dr. Spanggaard has received research support from MSD. The institution of Dr. Spanggaard has received research support from PUMA Biotechnology. The institution of Dr. Spanggaard has received research support from Orion Pharma. Dr. Spanggaard has received personal compensation in the range of $500-$4,999 for serving as a Reimbursement for travel-related expenses for the AAN2023 with Incyte.
Matthew B. Bevers, MD, PhD	Dr. Bevers has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for EBSCO. An immediate family member of Dr. Bevers has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for multiple law firms. Dr. Bevers has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for multiple law firms. The institution of Dr. Bevers has received research support from NINDS. The institution of an immediate family member of Dr. Bevers has received research support from AHRQ. The institution of an immediate family member of Dr. Bevers has received research support from NIH/Kowa Industries. The institution of an immediate family member of Dr. Bevers has received research support from NIDA.
Scott R. Plotkin, MD, PhD, FAAN	Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NFlection Therapeutics. Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Akouos. Dr. Plotkin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SonALAsense. Dr. Plotkin has stock in NFlection Therapeutics. Dr. Plotkin has stock in NF2 Therapeutics. Dr. Plotkin has stock in SonALAsense. Dr. Plotkin has received research support from Children's Tumor Foundation. Dr. Plotkin has received research support from Department of Defense. Dr. Plotkin has received research support from National Institutes of Health. Dr. Plotkin has received intellectual property interests from a discovery or technology relating to health care.
Jacqueline M. Behr, NP	Mrs. Behr has nothing to disclose.
Jennifer N. Serventi, PA	Ms. Serventi has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novocure.
Maya Viera, Other	Miss Viera has nothing to disclose.
Meredith Pescatello	Mrs. Pescatello has nothing to disclose.
Elle Fietsam	Miss Fietsam has nothing to disclose.
Ina Ly, MD	An immediate family member of Dr. Ly has received personal compensation for serving as an employee of Enanta Pharmaceuticals. Dr. Ly has received research support from Department of Defense. An immediate family member of Dr. Ly has received intellectual property interests from a discovery or technology relating to health care.
Bruce R. Korf, MD	Dr. Korf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SpringWorks Pharmaceuticals. Dr. Korf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Healx. Dr. Korf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Recursion. Dr. Korf has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genome Medical. Dr. Korf has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Infixion. Dr. Korf has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Journal of Human Genetics. Dr. Korf has stock in Genome Medical. The institution of Dr. Korf has received research support from NIH. The institution of Dr. Korf has received research support from Department of Defense. The institution of Dr. Korf has received research support from Children's Tumor Foundation. Dr. Korf has received publishing royalties from a publication relating to health care. Dr. Korf has received publishing royalties from a publication relating to health care. Dr. Korf has received publishing royalties from a publication relating to health care.
Ayah Al-Bzour	Miss Al-Bzour has nothing to disclose.
Ghayda'a N. Al-Majali	Ms. Al-Majali has nothing to disclose.
Saja Alzghoul	Miss Alzghoul has nothing to disclose.
Yaman Ahmed	Mr. Ahmed has nothing to disclose.
Zaid M. Khalefa	Mr. Khalefa has nothing to disclose.
Karisa C. Schreck, MD, PhD	Dr. Schreck has received personal compensation in the range of $0-$499 for serving as a Consultant for Nurix. Dr. Schreck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Schreck has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Advarra LLC. The institution of Dr. Schreck has received research support from Springworks Therapeutics. Dr. Schreck has received personal compensation in the range of $500-$4,999 for serving as a speaker with Springworks Therapeutics.
Ingo K. Mellinghoff, MD, FACP	Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Agios. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Black Diamond Therapeutics. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Voyager Therapeutics . Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kazia Therapeutics. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier . Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Agios. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Black Diamond Therapeutics. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Debiopharm Group. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Puma Biotechnology. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Voyager Therapeutics. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DC Europa Ltd. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kazia Therapeutics. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cardinal Health. Dr. Mellinghoff has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Servier . Dr. Mellinghoff has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ASCO/JCO. The institution of Dr. Mellinghoff has received research support from Amgen. The institution of Dr. Mellinghoff has received research support from General Electric. The institution of Dr. Mellinghoff has received research support from Lilly. The institution of Dr. Mellinghoff has received research support from Kazia Therapeutics. An immediate family member of Dr. Mellinghoff has received research support from Vigeo Therapeutics. The institution of an immediate family member of Dr. Mellinghoff has received research support from Samus Therapeutics. The institution of Dr. Mellinghoff has received research support from Erasca .
Ashley P. Ghiaseddin, MD, FAAN	Dr. Ghiaseddin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neosoma. Dr. Ghiaseddin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Servier. Dr. Ghiaseddin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aptitude Health. Dr. Ghiaseddin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Monteris Medical. Dr. Ghiaseddin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ONO Pharma USA. Dr. Ghiaseddin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novocure. Dr. Ghiaseddin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global Consulting. Dr. Ghiaseddin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Curio Science. Dr. Ghiaseddin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for The Lockwood Group. Dr. Ghiaseddin has stock in Viatris Inc.
Alissa A. Thomas, MD, FAAN	The institution of Dr. Thomas has received research support from Novocure. The institution of Dr. Thomas has received research support from Ono Pharmaceuticals.
Obada Ababneh	Mr. Ababneh has nothing to disclose.
Michal Nisnboym Ziv, MD	Dr. Nisnboym Ziv has nothing to disclose.

��ɫ��

��ɫ��